Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA

Sumitomo Mitsui Trust Group Inc. increased its stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,675 shares of the company’s stock after purchasing an additional 205 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Verona Pharma PLC American Depositary Share were worth $442,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in Verona Pharma PLC American Depositary Share by 5.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,940 shares of the company’s stock worth $183,000 after purchasing an additional 103 shares during the period. Geneos Wealth Management Inc. raised its holdings in Verona Pharma PLC American Depositary Share by 44.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock worth $40,000 after purchasing an additional 193 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Verona Pharma PLC American Depositary Share by 3.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,880 shares of the company’s stock worth $1,124,000 after purchasing an additional 394 shares during the period. Values First Advisors Inc. raised its holdings in Verona Pharma PLC American Depositary Share by 2.1% in the 2nd quarter. Values First Advisors Inc. now owns 25,661 shares of the company’s stock worth $2,427,000 after purchasing an additional 532 shares during the period. Finally, IFP Advisors Inc bought a new position in Verona Pharma PLC American Depositary Share in the 2nd quarter worth $52,000. 85.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VRNA has been the topic of a number of recent analyst reports. BTIG Research cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Cowen cut Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. TD Cowen cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Jefferies Financial Group reissued a “hold” rating and set a $107.00 price target (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, July 9th. Finally, Wolfe Research lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of Verona Pharma PLC American Depositary Share stock opened at $106.91 on Friday. The firm has a market cap of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. The business has a 50-day moving average price of $106.54 and a 200-day moving average price of $94.35. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. Verona Pharma PLC American Depositary Share has a twelve month low of $31.09 and a twelve month high of $106.93.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.14. The firm had revenue of $103.14 million during the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. Equities research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.